While all poly ADP-ribose polymerase (PARP) inhibitors improved progression-free survival, olaparib significantly extended overall survival (OS), making it a preferred option.

With historical data showing migraine to be underdiagnosed and undertreated, new guidance from the American College of ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the significance of triple-negative breast cancer ...

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...

A polypill for preventing cardiovascular disease has the potential to address health inequities and expand health care access ...

FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors ...

The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B ...

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons ...

Gladys Antelo-Allen of Camden Coalition discusses a new skills lab offering accessible learning modules with 12 microlessons on best practices for approaching complex care.

The FDA removed previously issued draft guidance on diversity in clinical trials from its website without public notice or ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Private equity hospital acquisitions in the US were associated with declines in patient care experience, particularly in ...